ACH · Accendra Health Inc/Va/
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| (Loss) income from continuing operations, net of tax, adjusted (non-GAAP) (Adjusted Net (Loss) I non-GAAP | -$17.41M | Six Months Ended June 30, 2026 | — |
| (Loss) income from continuing operations, net of tax, per common share, adjusted (non-GAAP) (Adj non-GAAP | -$0.19 | Three Months Ended June 30, 2026 | — |
| Active Patients | 2.9M | FY25A | — |
| Adjusted EBITDA (non-GAAP) non-GAAP | $118.46M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Commercial Payor Contracts | 2,500 | FY25A | — |
| DSO | 17.8 | the quarter ended June 30, 2026 filing | — |
| Free cash flow (non-GAAP) non-GAAP | -$27.11M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Interest paid | -$79M | Six Months Ended June 30, 2026 | — |
| Net debt (non-GAAP) non-GAAP | $1.71B | June 30, 2026 | — |
| Patient service equipment capital expenditures | -$44M | Three Months Ended June 30, 2026 | — |
| Adj. net income from continuing operations per share, Non-GAAP non-GAAP | $0.21 | 4Q25 | — |
| Adj. net income from continuing operations, Non-GAAP non-GAAP | $16.7M | 4Q25 | — |
| Operating cash flow | $154M | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Distribution — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACH
this stock
Accendra Health Inc/Va/
|
$78.44M | -66.0% | +3.1% | — | 6.9% |
|
MCK
Mckesson Corp
|
$101.32B | +5.9% | +3.1% | 23.3 | 3.1% |
|
COR
Cencora, Inc.
|
$59.89B | -7.1% | +9.3% | 23.3 | 2.7% |
|
CAH
Cardinal Health Inc
|
$54.69B | +14.4% | +14.2% | — | 2.8% |
|
HSIC
Henry Schein Inc
|
$10.00B | +18.8% | +5.9% | 26.2 | 5.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACH | -66.0% | -72.6% | -63.4% | -69.2% | -66.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -66.4% | -77.1% | -77.2% | -73.2% | -79.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.